Otezla (apremilast) is an oral tablet commonly used to treat plaque psoriasis in adults and children. Plaque psoriasis is an inflammatory skin condition that causes itchy, painful patches on the skin.

Otezla (apremilast) is a prescription drug that’s used to treat plaque psoriasis, psoriatic arthritis, and mouth sores related to Behçet’s disease in certain people. Otezla comes as an oral ...

apremilast (Otezla) oral tablets, deucravacitinib (Sotyktu) oral TYK 2 inhibitor, or methotrexate (Otrexup (PF), Trexall Tablets, Xatmep). Phototherapy. Just like with guttate psoriasis ...

Guttate psoriasis is a form of psoriasis that often appears in the wake of strep throat and other similar infections. It's characterized by the spontaneous outbreak of small, pink, teardrop-shaped ...

Amgen has announced the availability of Otezla (apremilast) in the US for paediatric patients with moderate to severe plaque psoriasis, [a skin lesion condition]. It is the first and only pill for ...

Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it prepares for competition from Bristol-Myers Squibb's much-touted rival deucravacitinib ...

Earlier this year, the U.S. Food and Drug Administration (FDA) approved Otezla for the treatment of moderate to severe plaque psoriasis in children and adolescents ages 6 and older who weigh at ...

Otezla is the first oral therapy approved for moderate to severe plaque psoriasis in this patient population. The Food and Drug Administration (FDA) has expanded the approval of Otezla ...

Otezla is now available in the U.S. to treat children and adolescents with moderate to severe plaque psoriasis. Otezla was approved earlier this year. Otezla is now available in the U.S. for the ...

That compared with 12.7% and 9.4% for those receiving placebo and 35.1% and 40.2% of patients on Otezla. PASI 75 is a measure on the psoriasis area and severity index. In other words, the overall ...

Amgen (NASDAQ:AMGN) today announced Otezla® (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food and Drug Administration (FDA) approved Otezla for the ...